• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于随机模拟和估计的他克莫司在韩国成年移植受者治疗药物监测中的药代动力学模型。

Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients.

机构信息

Pharmacometrics Institute for Practical Education and Training (PIPET), College of Medicine, The Catholic University of Korea.

Department of Pharmacology, College of Medicine, The Catholic University of Korea.

出版信息

Ther Drug Monit. 2022 Dec 1;44(6):729-737. doi: 10.1097/FTD.0000000000001006. Epub 2022 Jul 13.

DOI:10.1097/FTD.0000000000001006
PMID:35830880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9648981/
Abstract

BACKGROUND

Tacrolimus shows high variability in inter- and intraindividual pharmacokinetics (PK); therefore, it is important to develop an appropriate model for accurate therapeutic drug monitoring (TDM) procedures. This study aimed to develop a pharmacokinetic model for tacrolimus that can be used for TDM procedures in Korean adult transplant recipients by integrating published models with acquired real-world TDM data and evaluating clinically meaningful covariates.

METHODS

Clinical data of 1829 trough blood samples from 269 subjects were merged with simulated data sets from published models and analyzed using a nonlinear mixed-effect model. The stochastic simulation and estimation (SSE) method was used to obtain the final parameter estimates.

RESULTS

The final estimated values for apparent clearance, the volume of distribution, and absorption rate were 21.2 L/h, 510 L, and 3.1/h, respectively. The number of postoperative days, age, body weight, and type of transplant organs were the major clinical factors affecting tacrolimus PK.

CONCLUSIONS

A tacrolimus PK model that can incorporate published PK models and newly collected data from the Korean population was developed using the SSE method. Despite the limitations in model development owing to the nature of TDM data, the SSE method was useful in retrieving complete information from the TDM data by integrating published PK models while maintaining the variability of the model.

摘要

背景

他克莫司在个体间和个体内的药代动力学(PK)中表现出高度变异性;因此,开发一种合适的模型用于准确的治疗药物监测(TDM)程序非常重要。本研究旨在开发一种他克莫司的药代动力学模型,通过整合已发表的模型和获得的真实世界 TDM 数据,并评估有临床意义的协变量,将其用于韩国成年移植受者的 TDM 程序。

方法

将 269 名受试者的 1829 个谷浓度血样的临床数据与已发表模型的模拟数据集合并,并使用非线性混合效应模型进行分析。使用随机模拟和估计(SSE)方法获得最终参数估计值。

结果

最终估计的表观清除率、分布容积和吸收速率分别为 21.2 L/h、510 L 和 3.1/h。术后天数、年龄、体重和移植器官类型是影响他克莫司 PK 的主要临床因素。

结论

使用 SSE 方法开发了一种可以整合已发表 PK 模型和新收集的韩国人群数据的他克莫司 PK 模型。尽管由于 TDM 数据的性质限制了模型的开发,但 SSE 方法通过整合已发表的 PK 模型从 TDM 数据中检索完整信息,同时保持模型的变异性,在模型开发中非常有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0435/9648981/5c111bb61f73/tdm-44-729-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0435/9648981/a1695fd5b494/tdm-44-729-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0435/9648981/fcbc67141196/tdm-44-729-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0435/9648981/5c111bb61f73/tdm-44-729-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0435/9648981/a1695fd5b494/tdm-44-729-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0435/9648981/fcbc67141196/tdm-44-729-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0435/9648981/5c111bb61f73/tdm-44-729-g003.jpg

相似文献

1
Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients.基于随机模拟和估计的他克莫司在韩国成年移植受者治疗药物监测中的药代动力学模型。
Ther Drug Monit. 2022 Dec 1;44(6):729-737. doi: 10.1097/FTD.0000000000001006. Epub 2022 Jul 13.
2
Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.群体药代动力学建模与贝叶斯估算器设计在肺移植中用于他克莫司治疗药物监测。
Clin Pharmacokinet. 2012 Mar 1;51(3):175-86. doi: 10.2165/11594760-000000000-00000.
3
Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.采用 NONMEM 法根据 CYP3A5 基因型和临床因素预测成人肾移植受者他克莫司群体药代动力学参数。
Eur J Clin Pharmacol. 2013 Jan;69(1):53-63. doi: 10.1007/s00228-012-1296-4. Epub 2012 Jun 2.
4
Impact of Donor and Recipient Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients.供体和受者基因型对中国成人肝移植受者他克莫司群体药代动力学的影响。
Ann Pharmacother. 2020 Jul;54(7):652-661. doi: 10.1177/1060028019897050. Epub 2019 Dec 30.
5
A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.建立群体药代动力学模型预测成人肾移植受者他克莫司的起始个体剂量。
Br J Clin Pharmacol. 2019 Mar;85(3):601-615. doi: 10.1111/bcp.13838. Epub 2019 Jan 17.
6
A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients.评估成年早期肾移植受者全血和细胞内他克莫司高变异性的联合群体药代动力学模型。
Int Immunopharmacol. 2024 Aug 20;137:112535. doi: 10.1016/j.intimp.2024.112535. Epub 2024 Jun 21.
7
Population Pharmacokinetic Analysis for Model-Based Therapeutic Drug Monitoring of Tacrolimus in Chinese Han Heart Transplant Patients.中国汉族心脏移植患者中他克莫司基于模型的治疗药物监测的群体药代动力学分析。
Eur J Drug Metab Pharmacokinet. 2023 Jan;48(1):89-100. doi: 10.1007/s13318-022-00807-3. Epub 2022 Dec 8.
8
Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review.成人移植受者他克莫司的群体药代动力学模型:系统评价。
Clin Pharmacokinet. 2020 Nov;59(11):1357-1392. doi: 10.1007/s40262-020-00922-x.
9
Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients.中国心脏移植受者他克莫司的群体药代动力学分析。
Eur J Hosp Pharm. 2020 Mar;27(e1):e12-e18. doi: 10.1136/ejhpharm-2018-001764. Epub 2019 Jan 19.
10
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.中国肝移植患者他克莫司暴露量的群体药代动力学及贝叶斯估计
J Clin Pharm Ther. 2017 Dec;42(6):679-688. doi: 10.1111/jcpt.12599. Epub 2017 Aug 17.

引用本文的文献

1
Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools.基于模型的他克莫司精准给药:群体药动学模型的系统评价和软件工具的基准研究。
Clin Pharmacokinet. 2024 Oct;63(10):1407-1421. doi: 10.1007/s40262-024-01414-y. Epub 2024 Sep 20.
2
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.基于接受免疫治疗的晚期黑色素瘤患者的真实世界电子健康记录和图像数据来模拟肿瘤大小动态。
CPT Pharmacometrics Syst Pharmacol. 2023 Aug;12(8):1170-1181. doi: 10.1002/psp4.12983. Epub 2023 Jun 16.
3
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study.
早期在家测量阿达木单抗浓度以指导抗 TNF 精准给药:一项初步研究。
Eur J Drug Metab Pharmacokinet. 2023 Jul;48(4):377-385. doi: 10.1007/s13318-023-00835-7. Epub 2023 Jun 15.
4
Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients: Erratum.基于随机模拟和估计的韩国成年移植受者他克莫司治疗药物监测的药代动力学模型:勘误
Ther Drug Monit. 2023 Apr 1;45(2):285. doi: 10.1097/FTD.0000000000001076.